Lilly suspends late-stage trial for melanoma drug
Eli Lilly and Co. suspended a late-stage clinical trial of a medicine for skin-cancer patients after 12 patients in the study died.
Diseases
Articles
Q&A
Molecular biologist,David G. Skalnik will become associate dean for research and graduate education at the IUPUI School of Science in January. Since 1991, Skalnick has been a researcher at the Indiana University School of Medicine, leading a team of three in the study of epigenetics—factors that influence whether certain genes are turned on or turned off.
Study: Arthritis drug co-developed by Lilly shows promise
Lilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications for autoimmune diseases.
Lilly makes $300M deal for Philadelphia drug company
Eli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients with Alzheimer’s disease. The price could climb to $800 million if the agent is commercially successful.
UPDATE: Lilly, others see stock slide after drug rejection
Stock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
Lilly’s Erbitux shows mixed results in cancer studies
In combination with chemotherapy, the drug failed to help colon-cancer patients in a European trial but did delay the spread of breast cancer in some patients with a certain type of aggressive tumor.
Diabetes research pioneer Kirtley dies at 96
Diabetics who control their disease with pills instead of frequent insulin injections can thank Dr. William R. Kirtley, a
groundbreaking Eli Lilly researcher.
Lilly halts development of Alzheimer’s drug
Studies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical
giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through
2014.
Positron has billion-dollar hopes for medical-imaging scanner
A maker of medical imaging equipment that recently moved its headquarters to Fishers has grand plans to reach $1 billion in
sales and build a multimillion-dollar cyclotron facility in five years. But history shows Positron Corp. has been far better
at losing money than making it.
Indianapolis startup attacks Alzheimer’s disease
AgeneBio Inc. this month landed a $300,000 investment from the Indiana Seed Fund to fund operations, bolster its intellectual
property, and begin learning how to make a drug into a once-a-day pill.
Lilly still waiting on once-weekly Byetta
The U.S. Food and Drug Administration last week pushed its self-declared deadline for rendering an approval decision on the
drug Bydureon to Oct. 22. The previous deadline was in March.
New federal funds come with big goals
Indiana has now received nearly $50 million in federal bucks to digitize health care around the state. But the latest grant—$16
million to the Indiana Health Information Exchange—comes with specific, ambitious goals for health care providers.
Health care bill burns local tanning industry
With one of the nation’s largest tanning-bed manufacturers and dozens of salons in central Indiana, a 10-percent tax on tanning
could cost the region jobs.
IU incubator attracts East Coast biotech startup
Companion Diagnostics Inc. moves from Connecticut to the IU Emerging Technologies Center, hopes to create 30 high-paying jobs
by 2014.
IU cancer center names new director
Dr. Patrick J. Loehrer Sr. replaces Dr. Stephen D. Williams, the center’s founding director, who died of cancer in February
2009.
State health commissioner leaving for CDC
Dr. Judy Monroe, after five years as Indiana’s public health leader, will spearhead communication between federal and state
health agencies.
Enzon Pharmaceuticals sells Indy drug plant; 100 local jobs safe
New Jersey-based Enzon Pharmaceuticals Inc. has sold its Indianapolis plant that manufactures specialty drugs in a deal that
could top $300 million. The buyer says that the operations, which employ about 100, will remain in the city.
HICKS: New breast cancer recommendation not supported
Under the current proposal, the same type of groups that made the CDC’s recommendations will outline guidelines about which treatment will be offered under a government program.
Vera Bradley gives another $10M to IU cancer center
Previous gifts from the foundation to the cancer center have been used to hire 10 researchers working on breast cancer.